相关实验视频
Updated: Jul 13, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
用巴里西提尼布治疗的亚托皮炎患者的传染性不良事件
Flaminia Antonelli1,2, Dalma Malvaso1,2, Giacomo Caldarola1,2
1Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, 00168, Italy.
巴里西提尼布是一种JAK1-2抑制剂,已被批准用于中度至重度的亚托邦性皮炎. 临床试验表明感染,如上呼吸道感染,是常见的,但大多是轻度至中度的不良事件.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 巴里西提尼布是一种Janus激酶 (JAK) 1和2抑制剂.
- 它最近在欧洲和日本获得批准,用于治疗成年人中度至重度的亚托皮炎.
- 已批准的剂量为每天2mg和4mg.
研究的目的:
- 审查巴里西提尼布在阿托皮性皮肤炎患者的安全性.
- 专注于与巴里替尼治疗相关的传染性不良事件.
- 分析临床试验和现有文献的数据.
主要方法:
- 综合分析了来自八项临床试验的安全数据.
- 支持科学文献的审查.
- 专注于识别和分类传染性不良事件.
主要成果:
- 感染是最常见的治疗出现的不良事件.
- 大多数感染的严重程度为轻度至中度.
- 常见的感染包括上呼吸道感染和简单疹恶化.
结论:
- 巴里西替尼在阿托皮性皮肤炎中表现出一般可控的安全性,感染是最常见的不良事件.
- 大多数传染性不良事件是轻度至中度的.
- 需要进一步的现实世界数据来充分描述可能从这种治疗中受益最多的患者群体.
更多相关视频
09:32Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
相关概念视频
Allergic Drug Reactions
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Allergic Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...